## MODULE



This module is directed toward respiratory therapists, or others who administer ribavirin (Virazole), pentamidine (Nebupent) or tobramycin (Nebcin, "tobi") in an aerosolized form.

1.	During your career (including all jobs at this and other facilities), how long have you been administering aerosolized ribavirin, pentamidine or tobramycin?	<ul> <li>Less than 6 months</li> <li>At least 6 months but less than a year</li> <li>1-5 years</li> <li>6-10 years</li> <li>11-20 years</li> <li>More than 20 years</li> </ul>
2.	When have you received formal training at this facility on procedures for the safe handling of aerosolized medications?  Please ✓ all that apply.	<ul> <li>During orientation for your current job or task</li> <li>Once, but not at orientation</li> <li>Periodically, but less than once per year</li> <li>At least annually (i.e., one or more times every year</li> <li>Other (Please specify):</li> <li>Never received training at this facility</li> </ul>
3.	Have you seen written policies or standard procedures at this facility for administering aerosolized medications?	☐ Yes ☐ No
4.	Do you ever wear or take home any clothing (protective clothing or street clothes) which were worn when administering ribavirin, pentamidine or tobramycin at this facility?	☐ Yes ☐ No
5.	At any time in the past 7 calendar days did you administer aerosolized ribavirin, pentamidine or tobramycin?	Yes No Skip to Question 43
6.	At any time in the past 7 calendar days did you administer aerosolized ribavirin (Virazole)?	Yes No Skip to Question 14.

7.	During the past 7 calendar days, how many days did you administer aerosolized ribavirin?	Number of days(Please write a number from 1-7)
8.	During the past 7 calendar days, how much time did you typically spend within 5 feet of a patient during a single administration of ribavirin? (Include only the time you spent actually handling ribavirin, were present in the area during administration, and in clean-up. Do not include set-up time or time the patient was receiving the drug while you were not present.)	☐ Less than 5 minutes ☐ 5-9 minutes ☐ 10-14 minutes ☐ 15-19 minutes ☐ 20-24 minutes ☐ More than 24 minutes
9.	During the past 7 calendar days, what was the total number of times you administered aerosolized ribavirin? (If you administered ribavirin several times to the same patient, count each administration separately.)	☐ 1 time ☐ 2-3 times ☐ 4-5 times ☐ 6-10 times ☐ More than 10 times
10.	How does the total amount of time you administered aerosolized ribavirin during the past 7 calendar days compare with most weeks?	□ Past 7 days were about normal □ Past 7 days were less than normal □ Past 7 days were greater than normal
11.	During the past 7 calendar days, in which of the following areas did you ever administer aerosolized ribavirin? Please ✓ all that apply.	<ul> <li>□ a Patient's hospital room</li> <li>□ b. Clinic/department treatment room or area</li> <li>□ c. Patient's home</li> <li>□ d. Some other location (Please specify):</li> </ul>
	11A. From the location(s) checked above, please write the <b>letter</b> (a, b, c, or d) corresponding to the area where you most often administered aerosolized ribavirin during the past 7 calendar days.	Area most often administered

12.	During the past 7 calendar days, how often did you administer aerosolized ribavirin	Always	Sometimes	Never
	Inside a fully enclosed and sealed treatment chamber or booth?	. •		
	Inside a partially enclosed treatment hood or tent?			
	c. When no type of enclosure was being used?			
13.	During the past 7 calendar days when you administered aerosolized ribavirin, how often did you	Always	Sometimes	Never
	Inspect the aerosol generator for leaks or worn parts prior to use?			
	Use a nebulizer with an automatic shutoff valve?			
	c. Administer the medication in an isolation room under negative pressure (i.e., where air flows into the room from adjacent areas)?			
14.	At any time in the past 7 calendar days did you administer aerosolized pentamidine (Nebupent)?	☐ Yes ☐ No ■■■	Skip to Que	stion 22.
15.	During the past 7 calendar days, how many days did you administer aerosolized pentamidine?	Number of days (Please write a nur		
16.	During the past 7 calendar days, how much time did you typically spend within 5 feet of a patient during a single administration of pentamidine? (Include only the time you spent actually handling pentamidine, were present in the area during administration, and in clean-up. Do not include set-up time or time the patient was receiving the drug while you were not present.)	Less than 5 5-9 minutes 10-14 minut 15-19 minut 20-24 minut More than 2	des des des	

17.	During the past 7 calendar days, what was the total number of times you administered aerosolized pentamidine? (If you administered pentamidine several times to the same patient, count each administration separately.)	☐ 1 time ☐ 2-3 times ☐ 4-5 times ☐ 6-10 times ☐ More than					
18.	How does the amount of time you administered aerosolized pentamidine during the past 7 calendar days compare with most weeks?	Past 7 day	<ul> <li>□ Past 7 days were about normal</li> <li>□ Past 7 days were less than normal</li> <li>□ Past 7 days were greater than normal</li> </ul>				
19.	During the past 7 calendar days, in which of the following areas did you ever administer aerosolized pentamidine? Please ✓ all that apply.	□ b. Clinic/de area □ c. Patient's	s hospital room epartment treatme s home ther location (Plea				
	19A. From the location(s) checked above, please write the <b>letter</b> (a, b, c, or d) corresponding to the area where you most often administered aerosolized pentamidine during the past 7 calendar days.	Area most ofte	n administered	Ц			
20.	During the past 7 calendar days, how often di you administer aerosolized pentamidine	d Always	Sometimes	Never			
	Inside a fully enclosed and sealed treatment chamber or booth?						
	Inside a partially enclosed treatment hood or tent?	. 🗖					
	c. When no type of enclosure was being used?						

21.	During the past 7 calendar days when you administered aerosolized pentamidine, how often did you	Always	Sometimes	Never
	Inspect the aerosol generator for leaks or worn parts prior to use?			
	b. Use a nebulizer with an automatic shutoff valve?			
	c. Administer the medication in an isolation room under negative pressure (i.e., where air flows into the room from adjacent areas)?			_
22.	At any time in the past 7 calendar days did you administer aerosolized tobramycin (Nebcin, "tobi")?	☐ Yes☐ No ☐	Skip to Que	stion 30.
23.	During the past 7 calendar days, how many days did you administer aerosolized tobramycin?	Number of day (Please write a nu		
24.	During the past 7 calendar days, how much time did you typically spend within 5 feet of a patient during a single administration of tobramycin? (Include only the time you spent actually handling tobramycin, were present in the area during administration, and in clean-up. Do not include set-up time or time the patient was receiving the drug while you were not present.)	Less than 5 5-9 minutes 10-14 minu 15-19 minu 20-24 minu More than 2	tes tes	
25.	During the past 7 calendar days, what was the total number of times you administered aerosolized tobramycin? (If you administered tobramycin several times to the same patient, count each administration separately.)	☐ 1 time ☐ 2-3 times ☐ 4-5 times ☐ 6-10 times ☐ More than 1	10 times	
26.	How does the amount of time you administered aerosolized tobramycin during the past 7 calendar days compare with most weeks?	☐ Past 7 days	were about norma were less than no were greater than	rmal

27.	the fo	g the past 7 calendar days, in which of llowing areas did you ever administer olized tobramycin? Please ✓ all that	b. Clinic/area	at's hospital room department treatment's home other location (Plea	
	27A.	From the location(s) checked above, please write the <b>letter</b> (a, b, c, or d) corresponding to the area where you most often administered aerosolized tobramycin during the past 7 calendar days.	Area most of	ten administered	
28.		g the past 7 calendar days, how often did dminister aerosolized tobramycin	Always	Sometimes	Never
		side a fully enclosed and sealed atment chamber or booth?			
	b. Ins	side a partially enclosed treatment hood tent?			
	c. Wh	nen no type of enclosure was being ed?			
29.	admin	the past 7 calendar days when you istered aerosolized tobramycin, how did you	Always	Sometimes	Never
	a. Ins	pect the aerosol generator for leaks or rn parts prior to use?			
	b. Us	e a nebulizer with an automatic shutoff ve?			
	roc	minister the medication in an isolation om under negative pressure (i.e., where flows into the room from adjacent eas)?			

The following questions pertain to the use of personal protective equipment (PPE) during the preparation and delivery of aerosolized medications.

30.	wear garm	g the past 7 calendar days, did you a water resistant gown or outer ent while administering aerosolized rin, pentamidine or tobramycin?		So	Skip to Question 32. metimes ever
31.	\A/hat	word the reason(a) you did not always			
31.	wear	were the reason(s) you did not always a water resistant gown or outer	ш	1.	Potential for exposure to aerosolized medications is insignificant
	ribavi	arment while administering aerosolized bavirin, pentamidine or tobramycin? lease ✓ all that apply.		2.	Exposure to aerosolized medications is possible but the health hazard is insignificant
				3.	Not required by employer
				4.	Not provided by employer
				5.	Not standard practice
				6.	Too uncomfortable or difficult to use
				7.	Not readily or always available in wor area
				8.	Cross contamination to other areas is not a concern
				9.	Concerned about raising the patient's anxiety
				10.	. Other (Please specify):
	31A.	From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason you did not wear a water resistant gown or outer garment while administering aerosolized ribavirin, pentamidine or tobramycin.	Mos	st in	nportant reason
32.	wear	g the past 7 calendar days, did you protective gloves while handling in, pentamidine or tobramycin?			Skip to Question 34.

33.	What were the reason(s) you did not always wear protective gloves while handling		1.	Potential for exposure to aerosolized medications is insignificant
	ribavirin, pentamidine or tobramycin?  Please ✓ all that apply.		2.	Exposure to aerosolized medications is possible but the health hazard is insignificant
			3.	Not required by employer
			4.	Not provided by employer
			5.	Not standard practice
			6.	Too uncomfortable or difficult to use
			7.	Not readily or always available in work area
			8.	Cross contamination to other areas is not a concern
			9.	Concerned about raising the patient's anxiety
			10.	Other (Please specify):
			_	
	33A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one <b>most important</b> reason you did not wear protective gloves while handling ribavirin, pentamidine or tobramycin.			nportant reason
STOP	During the past 7 calendar days if you NE handling ribavirin, pentamidine or tobr	EVER amyo	wo in,	re protective gloves while skip to question 36.
34.	During the past 7 calendar days, did you perform any of the following activities while wearing <b>protective gloves</b> that had been used during the handling of ribavirin, pentamidine or tobramycin?			Vaa.
				Yes No -
	a. Answer the phone			
	b. Use a keyboard or calculator			
	c. Handle files or record cards			
	d. Eat or drink			
	e. Smoke			
				_

35.	During the past 7 calendar days, did you <b>ever</b> reuse protective gloves while handling ribavirin, pentamidine or tobramycin (reuse means remove and later put on the same gloves)?		Ye: No	
36.	During the past 7 calendar days, did you wear <b>eye protection</b> (safety glasses, goggles, face shield) while administering aerosolized ribavirin, pentamidine or tobramycin?			Mays Skip to Question 38.  metimes  ver
37.	What were the reason(s) you did not always wear eye protection while administering		1.	Potential for exposure to aerosolized medications is insignificant
	aerosolized ribavirin, pentamidine or tobramycin? Please ✓ all that apply.		2.	Exposure to aerosolized medications is possible but the health hazard is insignificant
			3.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used
			4.	Not required by employer
				Not provided by employer
				Not standard practice
				Too uncomfortable or difficult to use
			8.	Not readily or always available in work area
			9.	Concerned about raising the patient's anxiety
			10.	Other (Please specify):
	37A. From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason you did not wear eye protection while administering aerosolized ribavirin, pentamidine or tobramycin.	Мо	st im	nportant reason

	During the past 7 calendar days, did you wear <b>respiratory protection</b> , not including a surgical mask, while administering aerosolized ribavirin, pentamidine or tobramycin?		So	ways metimes ever Skip to Question 40.
39.	What type(s) of respirator(s) did you use? Please ✓ all that apply.		ca	sposable particulate respirator (also lled filtering face-piece respirator, e.g., 95)
				alf mask or full-face piece respirator with placeable filters or cartridges
			Po	owered air-purifying respirator (PAPR)
				on't know
40.	What were the reason(s) you did not always wear respiratory protection, not			Potential for exposure to aerosolized medications is insignificant
40.		_		medications is insignificant  Exposure to aerosolized medications
	pentamidine, or tobramycin? Please ✓ all that apply.			is possible but the health hazard is
				insignificant
			3.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used
			<ol> <li>3.</li> <li>4.</li> </ol>	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used
		0 0 0	4.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used
		0 0 0	4.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used  Not required by employer
		0 0 0 0	4. 5. 6.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used  Not required by employer  Not provided by employer
		0 0 0 0 0	4. 5. 6. 7.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used  Not required by employer  Not provided by employer  Not standard practice
		0 00000	4. 5. 6. 7. 8.	An engineering control (e.g., exhaust ventilation or an enclosure) is already being used  Not required by employer  Not provided by employer  Not standard practice  Too uncomfortable or difficult to use  Not readily or always available in work

	40A.	From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason you did not always wear respiratory protection while administering aerosolized ribavirin, pentamidine, or tobramycin.	Мо	st ir	mportant reason
41.	wear aeros	g the past 7 calendar days, did you booties while administering colized ribavirin, pentamidine or mycin?			Skip to Question 43. metimes ver
42.	wear	are the reason(s) you did not always booties while administering		1.	Potential for exposure to aerosolized medications is insignificant
		solized ribavirin, pentamidine or amycin? Please ✓ all that apply.		2.	Exposure to aerosolized medications is possible but the health hazard is insignificant
				3.	Not required by employer
					Not provided by employer
				5.	Not standard practice
				6.	Too uncomfortable or difficult to use
				7.	Not readily or always available in work area
				8.	Cross contamination to other areas is not a concern
				9.	Concerned about raising the patient's anxiety
				10.	Other (Please specify):
				_	
	42A.	From the reason(s) checked above, please write the number (1, 2, 3, etc.) of the one most important reason you did not always wear booties while administering aerosolized ribavirin, pentamidine or	Mos	st im	nportant reason

You have now completed this module. Thank you.

tobramycin.